UAE develops first fully AI-discovered cancer drug in record time

The UAE has produced its first fully AI-discovered drug candidate, marking a major step in the country's push to become a pharmaceutical innovation hub. The compound, called ISM0387, was developed by research teams at Insilico Medicine working with the Emirates Drug Establishment (EDE).

The achievement represents more than just a scientific breakthrough. It signals the UAE's shift from simply adopting advanced technologies to actively using them to create new pharmaceutical solutions and intellectual property.

How does it work?

ISM0387 targets an enzyme called PRMT5 and is designed to attack tumors with a specific genetic deletion (MTAP gene). This approach, known as synthetic lethality, allows the drug to be selective - it goes after cancer cells while leaving healthy cells largely untouched.

The compound shows particular promise against solid tumors, especially aggressive brain cancers that resist most current treatments. Key features include:

• Ability to cross the blood-brain barrier effectively
• Strong, dose-dependent tumor growth inhibition in lab studies
• Clear tumor suppression at 30 mg/kg daily doses over 20 days in animal models

The drug was created using Insilico Medicine's Chemistry42 platform, which combines more than 40 generative AI models to analyze biological and chemical data. The entire process happened in the UAE, from identifying targets to final candidate selection.

Why does it matter?

The speed of development is the real story here. The research team completed compound discovery in about six months, generating and testing more than 90 potential molecules. Traditional drug discovery at this stage typically takes over four years.

The full development process - from molecular design to final candidate selection - took less than 12 months. Compare that to conventional drug development, which can take more than 10 years and cost over $1 billion to bring a single treatment to market.

This timeline compression could change how quickly new treatments reach patients, particularly for diseases like aggressive brain cancer where time is critical.

The context

This development fits into the UAE's broader strategy to build a knowledge-based economy and reduce dependence on traditional industries. The country has been investing heavily in biotechnology infrastructure and creating regulatory frameworks that support innovation.

"This achievement will strengthen the UAE's position in global biotech value chains," said Saeed bin Mubarak Al Hajeri, Minister of State and Chairman of the Emirates Drug Establishment. "The country is building knowledge-based capabilities that support its role as an active partner in developing pharmaceutical solutions."

The success also reflects a global trend toward AI-accelerated drug discovery. Major pharmaceutical companies and biotech startups worldwide are racing to integrate artificial intelligence into their research processes, driven by the potential for faster, cheaper drug development.

Dr. Fatima Al Kaabi, Director-General of the Emirates Drug Establishment, emphasized that this goes beyond just creating new treatments. "It reflects ongoing efforts to build a strong national system that is redefining pharmaceutical security, moving from simply ensuring supply to having the capability to develop and sustain it locally," she said.

For patients, this could mean access to more precise and effective treatment options in the future. For the UAE, it demonstrates the country's ability to turn advanced technologies into valuable pharmaceutical solutions, strengthening drug security and its position as a hub for innovation-driven pharmaceutical industries.